Table 3 Treatment and outcomes of young adults with severe COVID-19
|  | Total n = 77 | Survivor n = 37 | Non-survivor n = 40 | P value |
|---|---|---|---|---|
Treatment | ||||
High-flow nasal cannula oxygen therapy | 15 (20%) | 6 (16%) | 9 (23%) | 0.487* |
Non-invasive mechanical ventilation | 28 (36%) | 2 (5%) | 26 (65%) |  < 0.001* |
Invasive mechanical ventilation | 27 (35%) | 0 (0) | 27 (68%) |  < 0.001* |
ECMO | 2 (3%) | 0 (0) | 2 (5%) | 0.494* |
Outcomes | ||||
ICU admission | 29 (38%) | 1 (3%) | 28 (70%) |  < 0.001* |
ICU length of stay, days | 10 (4–19) | . | 10 (4–17) | . |
Hospital length of stay, days | 19 (11–27) | 25 (21–33) | 11 (6–17) |  < 0.001 |
Time from illness onset to ICU admission, days | 16 (13–20) | . | 16 (13–21) | . |
Time from illness onset to death or discharge, days | 30 (22–39) | 38 (32–45) | 24 (19–29) |  < 0.001 |
SARS-CoV-2 RT-PCR test (-) | 43/77 (56%) | 35/37 (95%) | 8/40 (20%) |  < 0.001* |
Duration of viral shedding after COVID-19 onset, days | 22 (18–27) | 23 nnnn | 19 n | 0.054 |